Finding new ways that inflammatory signals affect cell function
Identify new mediators of proinflammatory cytokine signaling
This study is looking at how certain proteins involved in inflammation can mess with important cell signals in the body, and it's aimed at finding new ways to help people with conditions like arthritis and diabetes.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11055079 on NIH RePORTER |
What this research studies
This research investigates how proinflammatory cytokines, specifically interleukin 1β and tumor necrosis factor alpha, disrupt important cellular signaling pathways like AKT signaling, which is crucial for various physiological processes. The researchers will use advanced techniques such as RNA sequencing and CRISPR screening to identify the genes and factors that mediate these disruptions. By understanding these mechanisms, the research aims to uncover potential targets for therapeutic intervention in diseases linked to inflammation, such as arthritis and diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from inflammatory conditions such as arthritis or metabolic disorders like adult-onset diabetes.
Not a fit: Patients with non-inflammatory conditions or those not affected by metabolic disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for inflammatory diseases and metabolic disorders by restoring proper cellular signaling.
How similar studies have performed: Previous research has shown success in targeting inflammatory pathways to improve treatment outcomes in related conditions, indicating a promising avenue for this approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Li, Suzhao — University of Colorado Denver
- Study coordinator: Li, Suzhao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.